Impact of a Novel Valerian Extract on Sleep Quality, Relaxation, and GABA/Serotonin Receptor Activity in a Murine Model.

apoptosis caffeine melatonin neurotransmitters sleep disturbance valerian

Journal

Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981

Informations de publication

Date de publication:
27 May 2024
Historique:
received: 22 03 2024
revised: 19 04 2024
accepted: 26 04 2024
medline: 27 6 2024
pubmed: 27 6 2024
entrez: 27 6 2024
Statut: epublish

Résumé

Insomnia is a major global health issue, highlighting the need for treatments that are both effective and safe. Valerian extract, a traditional remedy for sleep problems, offers potential therapeutic options. This research examined the potential sleep-enhancing effects of VA (Valerian Pdr%2) in mice. The study evaluated sleep quality by comparing the impact of the VA extract against melatonin on brain activity, using electrocorticography (ECoG) to assess changes in brain waves. For this purpose, the study utilized two experimental models on BALB/c mice to explore the effects of caffeine-induced insomnia and pentobarbital-induced sleep. In the first model, 25 mice were assigned to five groups to test the effects of caffeine (caffeine, 7.5 mg/kg i.p) alone, caffeine with melatonin (2 mg/kg), or caffeine with different doses of valerian extract (100 or 300 mg/kg) given orally on brain activity, assessed via electrocorticography (ECoG) and further analyses on the receptor proteins and neurotransmitters. In the second model, a different set of 25 mice were divided into five groups to examine the impact of pentobarbital (42 mg/kg) alone, with melatonin, or with the valerian extract on sleep induction, observing the effects 45 min after administration. The study found that ECoG frequencies were lower in groups treated with melatonin and two doses of valerian extract (100 and 300 mg/kg), with 300 mg/kg showing the most significant effect in reducing frequencies compared to the caffeine control group, indicating enhanced sleep quality (

Identifiants

pubmed: 38929096
pii: antiox13060657
doi: 10.3390/antiox13060657
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : OmniActive Health Technologies (India)
ID : 2021-2
Organisme : Turkish Academy of Sciences
ID : 2021-1

Auteurs

Kazim Sahin (K)

Department of Animal Nutrition, Faculty of Veterinary Medicine, Firat University, 23119 Elazig, Türkiye.

Hasan Gencoglu (H)

Department of Biology, Faculty of Science, Firat University, 23119 Elazig, Türkiye.

Ahmet Kayhan Korkusuz (AK)

Department of Physiology, School of Medicine, Istanbul Medipol University, 34810 Istanbul, Türkiye.

Cemal Orhan (C)

Department of Animal Nutrition, Faculty of Veterinary Medicine, Firat University, 23119 Elazig, Türkiye.

İsmail Ertuğ Aldatmaz (İE)

Department of Physiology, School of Medicine, Istanbul Medipol University, 34810 Istanbul, Türkiye.

Fusun Erten (F)

Department of Veterinary Science, Pertek Sakine Genc Vocational School, Munzur University, 62500 Tunceli, Türkiye.

Besir Er (B)

Department of Biology, Faculty of Science, Firat University, 23119 Elazig, Türkiye.

Abhijeet Morde (A)

Research and Development, OmniActive Health Technologies, Mumbai 400013, India.

Muralidhara Padigaru (M)

Research and Development, OmniActive Health Technologies, Mumbai 400013, India.

Ertugrul Kilic (E)

Department of Physiology, Faculty of Medicine, Istanbul Medeniyet University, 34700 Istanbul, Türkiye.

Classifications MeSH